European urology最新文献

{"title":"Re: Thomas van Doeveren, Sebastiaan Remmers, Egbert R. Boevé, et al. Intravesical Instillation of Chemotherapy Before Radical Surgery for Upper Urinary Tract Urothelial Carcinoma: The REBACARE Trial. Eur Urol 2025;87:444–52","authors":"Han Luo, Xuewen Wang, Jiaqing Chen","doi":"10.1016/j.eururo.2025.03.028","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.03.028","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"49 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144165508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti’s Letter to the Editor re: Andreas Josefsson, Marianne Månsson, Kimia Kohestani, et al. Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial. Eur Urol 2024;86:223–9","authors":"Andreas Josefsson , Sigrid V. Carlsson , Hans Lilja , Rebecka Godtman , Jonas Hugosson","doi":"10.1016/j.eururo.2025.02.027","DOIUrl":"10.1016/j.eururo.2025.02.027","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 6","pages":"Pages e112-e113"},"PeriodicalIF":25.3,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144153939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Congress Calendar","authors":"","doi":"10.1016/j.eururo.2025.04.014","DOIUrl":"10.1016/j.eururo.2025.04.014","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 6","pages":"Pages e119-e120"},"PeriodicalIF":25.3,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144153940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platinum Hall of Fame","authors":"","doi":"10.1016/j.eururo.2025.04.013","DOIUrl":"10.1016/j.eururo.2025.04.013","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 6","pages":"Pages e99-e110"},"PeriodicalIF":25.3,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144154003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Magnetic Resonance Imaging–led Risk-adapted Active Surveillance for Prostate Cancer: Updated Results from a Large Cohort Study","authors":"Cameron Englman, Busola Adebusoye, Davide Maffei, Vasilis Stavrinides, Joshua Bridge, Alex Kirkham, Clare Allen, Louise Dickinson, Doug Pendse, Shonit Punwani, Navin Ramachandran, Chun Wah So, Aiman Haider, Alex Freeman, Alistair Grey, Clement Orczyk, John Withington, Karen Wilkinson, Veeru Kasivisvanathan, Mark Emberton, Caroline M. Moore","doi":"10.1016/j.eururo.2025.03.019","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.03.019","url":null,"abstract":"<h3>Background and objective</h3>Magnetic resonance imaging (MRI)-led active surveillance (AS) for prostate cancer uses prostate-specific antigen (PSA) and MRI for regular monitoring with biopsy only when indicated by changes in MRI or PSA density.<h3>Methods</h3>This clinical cohort, which started AS between February 2000 and July 2023, includes those with (1) Gleason score (GS) ≤3 + 4, (2) PSA &lt;20 ng/ml, and (3) at least two MRI scans. The primary outcome was event-free survival (EFS) defined as histological upgrade to GS ≥4 + 3 or transition to treatment. Patients were risk stratified by baseline MRI visibility and Gleason pattern 4, and Kaplan-Meier curves were used to compare groups.<h3>Key findings and limitations</h3>The cohort consisted of 1150 patients with a median follow-up of 64 mo per person overall (quartiles: 32, 107). At baseline, of these 1150 patients, 412 (36%) had GS 3 + 4, 627 (55%) had an MRI-visible lesion, and 201 (17%) had MRI-visible Gleason 3 + 4 disease. The EFS rate at 5 yr was 91% (95% confidence interval: 88–94%) for nonvisible GS 3 + 3, 71% (65–78%) for MRI-visible GS 3 + 3, 70% (63–78%) for nonvisible GS 3 + 4, and 44% (35–54%) for MRI-visible GS 3 + 4. A total of 487 patients had follow-up biopsies, with 74 having more than one, and histological upgrade to GS ≥4 + 3 was uncommon, occurring in 67 patients. Progression to nodal or bone metastases occurred in ten patients and only in those who had declined the recommended follow-up MRI and/or biopsies. Thirty patients chose treatment despite having stable characteristics, and 31 were lost to follow-up.<h3>Conclusions and clinical implications</h3>MRI visibility and secondary Gleason pattern 4 at baseline are associated with progression to treatment and to primary Gleason pattern 4 during MRI-led AS.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"50 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144154002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consolidative Surgery for Advanced Urothelial Carcinoma Following Induction Enfortumab Vedotin and/or Immune Checkpoint Inhibitor Therapy: A Multicenter Analysis","authors":"Daniel S. Roberson, Vidit Sharma, Stephen A. Boorjian, Matthew T. McLeay, Giuseppe Reitano, Mimi V. Nguyen, Jacob J. Orme, Daniel S. Childs, Lance C. Pagliaro, Aaron M. Potretzke, R.Jeffrey Karnes, Paras Shah, Andrew Zganjar, Timothy Lyon, Mark D. Tyson, Abhinav Khanna","doi":"10.1016/j.eururo.2025.05.015","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.05.015","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"152 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144145883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maximizing Outcomes with Chemoimmunotherapy in Lymph Node–only Metastatic Urothelial Cancer: Targeting a Favorable Subgroup","authors":"Charles B. Nguyen, Wesley Yip","doi":"10.1016/j.eururo.2025.05.018","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.05.018","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"25 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144122622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer","authors":"Marie-Pier St-Laurent, Parminder Singh, David J. McConkey, M. Scott Lucia, Vadim S. Koshkin, Kelly L. Stratton, Trinity J. Bivalacqua, Wassim Kassouf, Sima P. Porten, Rick Bangs, Melissa Plets, Ian M. Thompson, Joshua J. Meeks, Vincent M. Caruso, Ceressa T. Ward, Brian C. Mazzarella, Kevin G. Phillips, Vincent T. Bicocca, Trevor G. Levin, Seth P. Lerner, Peter C. Black","doi":"10.1016/j.eururo.2025.03.023","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.03.023","url":null,"abstract":"As new treatments for bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC) emerge, better methods are needed to guide therapeutic decisions. This study analyzed urine tumor DNA (utDNA) from patients treated with atezolizumab in the SWOG S1605 trial to determine whether utDNA profiling can stratify the risk of treatment failure. Urine samples were analyzed using the UroAmp assay at baseline and 3 mo from 89 and 77 patients, respectively. Only 13% of UroAmp-positive patients at baseline achieved a complete response at 6 mo compared with 71% of UroAmp-negative patients (<em>p</em> &lt; 0.001). The 18-mo event-free survival (EFS) was significantly lower for UroAmp-positive patients at baseline (23%) than for UroAmp-negative patients (51%; hazard ratio [HR] 2.8, <em>p</em> &lt; 0.001). Among patients with no clinical evidence of disease at 3 mo (<em>n</em> = 51), the 18-mo EFS was 38% for UroAmp-positive and 86% for UroAmp-negative (HR 3.5, <em>p</em> = 0.01) patients. These findings suggest that utDNA profiling at baseline and after 3 mo of treatment can help identify patients with BCG-unresponsive NMIBC who are less likely to benefit from systemic immunotherapy.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"88 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144114334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolving Risk of Urinary Adverse Events Across Localized Prostate Cancer Treatments: A Propensity-weighted Analysis of Surveillance, Epidemiology and End Results-Medicare Data","authors":"Kevin D. Li, Marvin N. Carlisle, Stephanie Jarosek, Hiren V. Patel, Anna Faris, Sean P. Elliott, Matthew R. Cooperberg, Peter R. Carroll, Benjamin N. Breyer","doi":"10.1016/j.eururo.2025.05.014","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.05.014","url":null,"abstract":"Prostate cancer treatments can cause long-term urinary adverse events (UAEs), but time-varying risks across treatments remain understudied. Using Surveillance, Epidemiology and End Results-Medicare data, we evaluated men aged ≥66 yr with localized prostate cancer treated with radical prostatectomy (RP), external beam radiotherapy (EBRT), brachytherapy (BT), EBRT + BT, RP + EBRT, or ablation between 2000 and 2017. The primary outcome was any UAE requiring a procedure, with follow-up from treatment initiation and censoring at disease progression. Kaplan-Meier analysis was used to estimate the UAE cumulative incidence and the propensity-weighted restricted mean survival time (RMST) to quantify mean UAE-free survival at 18 yr. The cohort included 166 581 patients: 40% received EBRT, 30% RP, 14% BT + EBRT, 12% BT, 3.1% RP + EBRT, and 1.7% ablation. Combined therapy carried the highest risk, with other modalities showing time-dependent changes. At 18 yr, the UAE risk was highest for RP + EBRT (41%), followed by BT + EBRT (35%), EBRT (29%), RP (23%), and BT (22%). Adjusted RMST to 18 yr was shortest for RP + EBRT (13.1 yr) and longest for BT (15.8 yr) and ablation (15.6 yr). In comparison to RP (15.1 yr), UAE-free survival was 2.0 yr shorter with RP + EBRT (RMST ratio 0.87; <em>p</em> &lt; 0.001) and 0.2 yr shorter with EBRT + BT (RMST ratio 0.99; <em>p</em> &lt; 0.001). The balance between oncologic efficacy and long-term urinary toxicity is key to treatment selection.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"254 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144122621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Abdominal Noncontrast Computed Tomography Scanning to Screen for Kidney Cancer and Other Abdominal Pathology Within Community-based Computed Tomography Screening for Lung Cancer: Results of the Yorkshire Kidney Screening Trial","authors":"Teele Kuusk, Maria Carmen Mir","doi":"10.1016/j.eururo.2025.05.002","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.05.002","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"38 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144104097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}